{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:41Z","timestamp":1793805941574,"version":"4.6.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013748","name":"The Hope Foundation for Cancer Research","doi-asserted-by":"publisher","award":["Career Engagement Award"],"award-info":[{"award-number":["Career Engagement Award"]}],"id":[{"id":"10.13039\/100013748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.06.026","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:26:34Z","timestamp":1784924794000},"page":"343-356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ideal candidates for bladder preservation in muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"44","author":[{"given":"Japneet K.","family":"Oberoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie K.","family":"Ballas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8548-6948","authenticated-orcid":false,"given":"Parminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.06.026_bib0001","unstructured":"A. C. Society. \u201cKey statistics for bladder cancer.\u201d https:\/\/www.cancer.org\/cancer\/bladder-cancer\/about\/key-statistics.html (accessed 08\/24\/2025)."},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.026_bib0002","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/JU.0000000000000350","article-title":"A nationwide, population based analysis of patients with organ confined, muscle invasive bladder cancer not receiving curative intent therapy in Sweden from 1997 to 2014","volume":"202","author":"Westergren","year":"2019","journal-title":"J Urol"},{"issue":"10364","key":"10.1016\/j.urolonc.2026.06.026_bib0003","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.06.026_bib0004","unstructured":"A randomized phase 3 study evaluating cystectomy with perioperative pembrolizumab and cystectomy with perioperative enfortumab vedotin and pembrolizumab versus cystectomy alone in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (KEYNOTE-905\/EV-303) Available: https:\/\/clinicaltrials.gov\/study\/NCT03924895. (accessed 02\/12\/2026)"},{"key":"10.1016\/j.urolonc.2026.06.026_bib0005","unstructured":"A phase III, randomized, open-label, multi-center, global study to determine the efficacy and safety of durvalumab in combination with gemcitabine+cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in patients with muscle-invasive bladder cancer Available: https:\/\/clinicaltrials.gov\/study\/NCT03732677. (accessed 02\/12\/2026)."},{"issue":"7_suppl","key":"10.1016\/j.urolonc.2026.06.026_bib0006","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630","article-title":"Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study","volume":"44","author":"Galsky","year":"2026","journal-title":"J Clin Oncol"},{"issue":"10139","key":"10.1016\/j.urolonc.2026.06.026_bib0007","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/S0140-6736(18)30996-6","article-title":"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial,","volume":"391","author":"Parekh","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.026_bib0008","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/JU.0000000000001360","article-title":"Electronic rapid fitness assessment identifies factors associated with adverse early postoperative outcomes following radical cystectomy","volume":"205","author":"Chesnut","year":"2021","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.026_bib0009","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.euf.2017.12.011","article-title":"A simplified frailty index to predict outcomes after radical cystectomy","volume":"5","author":"Sathianathen","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.026_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.026_bib0011","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.clon.2021.03.015","article-title":"Bladder preservation with radiotherapy: the patient perspective","volume":"33","author":"Costin","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.026_bib0012","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MOU.0000000000000601","article-title":"Trimodality therapy for bladder cancer: modern management and future directions,","volume":"29","author":"Pham","year":"2019","journal-title":"Curr Opin Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.026_bib0013","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2016.08.023","article-title":"Quality of life in long-term survivors of muscle-invasive bladder cancer","volume":"96","author":"Mak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.026_bib0014","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/01.ju.0000093721.23249.c3","article-title":"Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors,","volume":"170","author":"Zietman","year":"2003","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.026_bib0015","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bju.13900","article-title":"Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy","volume":"120","author":"Huddart","year":"2017","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.026_bib0016","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/COC.0000000000000471","article-title":"Comparison of outcomes in patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder preservation","volume":"42","author":"Zhong","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.026_bib0017","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12094-023-03264-9","article-title":"Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival","volume":"26","author":"Tang","year":"2024","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.026_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102405","article-title":"Clinical and pathological predictors for occult lymph node involvement in patients with clinical node-negative bladder cancer undergoing radical cystectomy","volume":"23","author":"Jaime-Casas","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"34","key":"10.1016\/j.urolonc.2026.06.026_bib0019","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.026_bib0020","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.026_bib0021","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0022-5347(17)47381-2","article-title":"Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival","volume":"134","author":"Shipley","year":"1985","journal-title":"J Urol"},{"issue":"14","key":"10.1016\/j.urolonc.2026.06.026_bib0022","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","article-title":"Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results","volume":"20","author":"R\u00f6del","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.026_bib0023","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.026_bib0024","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijrobp.2023.07.027","article-title":"Disease-free survival of patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder-preserving therapy: a nationwide study","volume":"118","author":"Br\u00fcck","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.026_bib0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2025.03.017","article-title":"Bladder preservation strategies in muscle-invasive Bladder Cancer: recommendations from the International Bladder Cancer Group","volume":"89","author":"Gupta","year":"2026","journal-title":"Eur Urol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2026.06.026_bib0026","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS586","article-title":"INTACT: phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer\u2014SWOG\/NRG1806","volume":"38","author":"Singh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.urolonc.2026.06.026_bib0027","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.3390\/cancers14194674","article-title":"Optimized adaptive radiotherapy with individualized plan library for muscle-invasive bladder cancer using internal target volume generation","volume":"14","author":"Jo","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.026_bib0028","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","article-title":"Multiparametric Magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting And Data System)","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.06.026_bib0029","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1007\/s00330-021-07765-5","article-title":"The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study","volume":"31","author":"Metwally","year":"2021","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.026_bib0030","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.euo.2021.01.005","article-title":"Staging 18F-fluorodeoxyglucose positron emission tomography\/computed tomography changes treatment recommendation in invasive bladder cancer","volume":"5","author":"Voskuilen","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.026_bib0031","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3233\/BLC-240036","article-title":"Eligibility and endpoints for clinical trials in trimodality therapy for bladder cancer","volume":"10","author":"Singh","year":"2024","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.026_bib0032","doi-asserted-by":"crossref","first-page":"132.e1","DOI":"10.1016\/j.urolonc.2020.07.016","article-title":"Impact of noninvasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy on bladder-sparing strategy in patients with muscle-invasive bladder cancer","volume":"39","author":"Onishi","year":"2021","journal-title":"Urol Oncol"},{"issue":"16","key":"10.1016\/j.urolonc.2026.06.026_bib0033","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.026_bib0034","doi-asserted-by":"crossref","first-page":"76.e19","DOI":"10.1016\/j.urolonc.2019.09.003","article-title":"Clinically node-positive (cN+) urothelial carcinoma of the bladder treated with chemotherapy and radical cystectomy: clinical outcomes and development of a postoperative risk stratification model","volume":"38","author":"Al-Alao","year":"2020","journal-title":"Urol Oncol"},{"issue":"27","key":"10.1016\/j.urolonc.2026.06.026_bib0035","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.23.00725","article-title":"Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer","volume":"41","author":"Swinton","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.026_bib0036","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jitc-2022-006551","article-title":"Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023","volume":"11","author":"Joshi","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.urolonc.2026.06.026_bib0037","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.026_bib0038","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1200\/JCO.1997.15.3.1022","article-title":"Bladder preservation by combined modality therapy for invasive bladder cancer","volume":"15","author":"Kachnic","year":"1997","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.026_bib0039","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1634\/theoncologist.5-6-471","volume":"5","author":"Kaufman","year":"2000","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.026_bib0040","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.urology.2008.09.036","article-title":"Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy","volume":"73","author":"Kaufman","year":"2009","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.urolonc.2026.06.026_bib0041","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","volume":"14","author":"Mitin","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.026_bib0042","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.18.00537","article-title":"Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712-a randomized Phase II trial","volume":"37","author":"Coen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.urolonc.2026.06.026_bib0043","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS720","article-title":"Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC)","volume":"42","author":"Gupta","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.06.026_bib0044","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/jjco\/hys105","article-title":"Analysis of intravesical recurrence after bladder-preserving therapy for muscle-invasive bladder cancer","volume":"42","author":"Onozawa","year":"2012","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.026_bib0045","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.urolonc.2008.07.005","article-title":"Combined modality treatment with bladder preservation for muscle invasive bladder cancer","volume":"28","author":"Sabaa","year":"2010","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.026_bib0046","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S0022-5347(17)39122-X","article-title":"Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis","volume":"142","author":"Gospodarowicz","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.026_bib0047","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024)","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.026_bib0048","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eururo.2016.12.002","article-title":"Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy","volume":"72","author":"Krasnow","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.026_bib0049","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/JU.0000000000004160","article-title":"The impact of histologic subtypes on clinical outcomes after radiation-based therapy for muscle-invasive bladder cancer","volume":"212","author":"Halstuch","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.026_bib0050","first-page":"38","article-title":"A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database","volume":"15","author":"Fischer-Valuck","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.urolonc.2026.06.026_bib0051","first-page":"30","article-title":"Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: an analysis of the National Cancer Database","volume":"26","author":"Janopaul-Naylor","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.06.026_bib0053","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1464-410X.2012.11455.x","article-title":"Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy","volume":"111","author":"Zapatero","year":"2013","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.026_bib0054","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.urology.2012.07.045","article-title":"Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy","volume":"80","author":"Peyromaure","year":"2012","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.026_bib0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.urology.2003.09.018","article-title":"Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution","volume":"63","author":"Peyromaure","year":"2004","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.026_bib0056","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijrobp.2008.11.030","article-title":"Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer","volume":"75","author":"Lin","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.026_bib0057","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.026_bib0058","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.eururo.2020.11.036","article-title":"Outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy followed by (Chemo)radiotherapy in the BC2001 trial","volume":"79","author":"Hussain","year":"2021","journal-title":"Eur Urol"},{"issue":"33","key":"10.1016\/j.urolonc.2026.06.026_bib0059","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.026_bib0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijrobp.2024.08.036","article-title":"Effect of complete transurethral resection on oncologic outcomes after radiation therapy for muscle-invasive bladder cancer","volume":"121","author":"Avolio","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.026_bib0061","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12894-020-00733-z","article-title":"Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients","volume":"20","author":"Hamid","year":"2020","journal-title":"BMC Urol"},{"issue":"16","key":"10.1016\/j.urolonc.2026.06.026_bib0062","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"Griffiths","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.026_bib0063","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clgc.2021.03.007","article-title":"Trimodality therapy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"19","author":"Royce","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.026_bib0065","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.euo.2024.01.014","article-title":"Benefit of neoadjuvant cisplatin-based chemotherapy for invasive bladder cancer patients treated with radiation-based therapy in a real-world setting: an inverse probability treatment weighted analysis","volume":"7","author":"Kool","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.026_bib0066","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.juro.2018.05.078","article-title":"Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study","volume":"200","author":"Mazza","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.026_bib0067","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.urology.2017.09.003","article-title":"Outcomes following clinical complete response to Neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder in patients refusing radical cystectomy","volume":"111","author":"Robins","year":"2018","journal-title":"Urology"},{"issue":"11","key":"10.1016\/j.urolonc.2026.06.026_bib0068","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.026_bib0069","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.juro.2009.01.115","article-title":"A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219)","volume":"181","author":"deVere White","year":"2009","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.026_bib0070","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clgc.2018.05.008","article-title":"FDG-PET\/CT for assessing the response to neoadjuvant chemotherapy in bladder cancer patients","volume":"16","author":"Soubra","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.026_bib0071","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.eururo.2019.12.016","article-title":"Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings from the PURE-01 study","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.026_bib0072","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1442-2042.2002.00443.x","article-title":"Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: a phase II trial","volume":"9","author":"Sousa-Escand\u00f3n","year":"2002","journal-title":"Int J Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.06.026_bib0073","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/cncr.32048","article-title":"Delays in radical cystectomy for muscle-invasive bladder cancer","volume":"125","author":"Chu","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.026_bib0074","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.eururo.2017.03.019","article-title":"Curative treatment for muscle invasive bladder cancer in elderly patients: a systematic review","volume":"73","author":"Fonteyne","year":"2018","journal-title":"Eur Urol"},{"issue":"26","key":"10.1016\/j.urolonc.2026.06.026_bib0075","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol."},{"issue":"8","key":"10.1016\/j.urolonc.2026.06.026_bib0076","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.026_bib0077","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000499263","article-title":"The usefulness of the modified frailty index for muscle-invasive bladder cancer patients treated with radical cystectomy","volume":"14","author":"Voskamp","year":"2020","journal-title":"Curr Urol."},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.026_bib0078","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.026_bib0079","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.semradonc.2022.10.007","article-title":"Myths about bladder preservation in muscle-invasive bladder cancer","volume":"33","author":"Elumalai","year":"2023","journal-title":"Semin Radiat Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.026_bib0080","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1200\/JCO.2010.31.5721","article-title":"Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer","volume":"29","author":"Choudhury","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.026_bib0081","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s11912-025-01657-3","article-title":"Current State of bladder preservation in high grade non-muscle invasive bladder cancer and localized muscle invasive bladder cancer","volume":"27","author":"Popli","year":"2025","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.1016\/j.urolonc.2026.06.026_bib0082","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1080\/14737140.2018.1535314","article-title":"Trimodal therapy for muscle-invasive bladder cancer","volume":"18","author":"Mathes","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.026_bib0083","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0090-4295(02)01650-3","article-title":"Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer","volume":"60","author":"Shipley","year":"2002","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.026_bib0084","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.juro.2011.09.159","article-title":"Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer","volume":"187","author":"Eswara","year":"2012","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.026_bib0085","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2009.12.002","article-title":"Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis","volume":"57","author":"Ramani","year":"2010","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.06.026_bib0086","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1002\/cam4.5840","article-title":"Utilising alternative cystoscopic schedules to minimise cost and patient burden after trimodality therapy for muscle-invasive bladder cancer","volume":"12","author":"Krishnatry","year":"2023","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.026_bib0087","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 Guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.026_bib0088","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.026_bib0089","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"T Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"10.1016\/j.urolonc.2026.06.026_bib0090","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1056\/NEJMe2515777","article-title":"Enfortumab Vedotin plus Pembrolizumab as perioperative therapy","volume":"394","author":"Singh","year":"2026","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.06.026_bib0091","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4601","article-title":"KEYNOTE-905\/EV-303: a phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC)","volume":"41","author":"Necchi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.026_bib0092","unstructured":"Single arm phase II study of bladder preservation with immunoradiotherapy after a clinically meaningful response to neoadjuvant therapy in patients with muscle invasive bladder cancer (BRIGHT) Available: https:\/\/clinicaltrials.gov\/study\/NCT07061964. (accessed 06\/18\/2026)."},{"key":"10.1016\/j.urolonc.2026.06.026_bib0093","unstructured":"Enfortumab vedotin in combination with pembrolizumab vs concurrent chemoradiotherapy (cCRT) in people with muscle invasive bladder cancer (EV-309). Available: https:\/\/clinicaltrials.gov\/study\/NCT07566156. (accessed 06\/18\/2026)."},{"key":"10.1016\/j.urolonc.2026.06.026_bib0094","unstructured":"HCRN GU22-598: phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder. J Clin Oncol. [accessed 18 June, 2026]. Available: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2026.44.7_suppl.TPS891"},{"issue":"7_suppl","key":"10.1016\/j.urolonc.2026.06.026_bib0095","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.TPS885","article-title":"EV-PRIME: phase ib\/II study of enfortumab vedotin and pembrolizumab combined with radiotherapy as a bladder-sparing trimodality therapy in muscle invasive bladder cancer","volume":"44","author":"Koshkin","year":"2026","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.urolonc.2026.06.026_bib0096","unstructured":"A phase II trial of risk enabled therapy after neoadjuvant immunochemotherapy for bladder cancer Available: https:\/\/clinicaltrials.gov\/study\/NCT04506554. (accessed 02\/12\/2026)"},{"key":"10.1016\/j.urolonc.2026.06.026_bib0097","unstructured":"A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations Available: https:\/\/clinicaltrials.gov\/study\/NCT03609216. (accessed 02\/12\/2026)."},{"issue":"7_suppl","key":"10.1016\/j.urolonc.2026.06.026_bib0098","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA632","article-title":"Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): integrated analysis of the RETAIN trials","volume":"44","author":"Ghatalia","year":"2026","journal-title":"J Clin Oncol"},{"issue":"7_suppl","key":"10.1016\/j.urolonc.2026.06.026_bib0099","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.636","article-title":"Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA","volume":"44","author":"van der Heijden","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:28:36Z","timestamp":1793802516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":97,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926005843"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.026","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ideal candidates for bladder preservation in muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}